Corticosteroids may restore sense of smell in COVID-19 patients

COVID-19 is known to cause loss of smell in certain patients. While this symptom is generally temporary, approximately 10% of patients may suffer from it for 6 months or more.

EMA pins lack of long-term data as rationale for Novartis’ failed Vijoice bid – Pharmaceutical Technology

Share this article The European Medicines Agency (EMA) released a report detailing the reasons for the withdrawal of Novartis marketing authorisation application for Vijoice. Credit:

March 14, 2024

Gabapentin No Help for Lingering COVID-Induced Olfactory Dysfunction

Treatment with oral gabapentin did not improve olfactory dysfunction that remained 3 months after a COVID-19 infection, the randomized GRACE trial showed. Of 44 patients

September 22, 2023

Top Cancer Centers; Phase III Win in Prostate Cancer; Screening Recs for Anal Cancer

U.S. News & World Report released its annual ranking of top cancer centers. Darolutamide (Nubeqa) plus androgen deprivation therapy (ADT) improved radiologic progression-free survival over

July 20, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.